Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?

  • Read more about Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?

Nanoparticle Delivery of Angiogenic Gene Therapy. Save the Vessels, Save the Lung!

  • Read more about Nanoparticle Delivery of Angiogenic Gene Therapy. Save the Vessels, Save the Lung!

Equipoise and Acumen in Pediatric Acute Respiratory Distress Syndrome Research.

  • Read more about Equipoise and Acumen in Pediatric Acute Respiratory Distress Syndrome Research.

Pulmonary Vascular Disease in Premature Infants. Early Predictive Models of Late Respiratory Morbidity.

  • Read more about Pulmonary Vascular Disease in Premature Infants. Early Predictive Models of Late Respiratory Morbidity.

Early Plasma Matrix Metalloproteinase Profiles. A Novel Pathway in Pediatric Acute Respiratory Distress Syndrome.

  • Read more about Early Plasma Matrix Metalloproteinase Profiles. A Novel Pathway in Pediatric Acute Respiratory Distress Syndrome.

Metagenomic Sequencing Detects Respiratory Pathogens in Hematopoietic Cellular Transplant Patients.

  • Read more about Metagenomic Sequencing Detects Respiratory Pathogens in Hematopoietic Cellular Transplant Patients.

The Prescient Prognosticator? Hepatoma-derived Growth Factor in Pulmonary Hypertension.

  • Read more about The Prescient Prognosticator? Hepatoma-derived Growth Factor in Pulmonary Hypertension.

Understanding the Short- and Long-Term Respiratory Outcomes of Prematurity and Bronchopulmonary Dysplasia.

  • Read more about Understanding the Short- and Long-Term Respiratory Outcomes of Prematurity and Bronchopulmonary Dysplasia.

Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension.

  • Read more about Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension.

Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension.

  • Read more about Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension.

Pagination

  • Previous page ‹‹
  • Page 2
  • Next page ››
Subscribe to American journal of respiratory and critical care medicine

Pediatrics Home

MAKE A GIFT

© 2022 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                              Accessibility  Privacy Policy  Terms of Use  A-Z Website List